We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aortech International Plc | AOR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 126.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 126.50 |
| Top Posts |
|---|
Posted at 13/6/2020 16:35 by bones Something for the weekend? This 10 year chart shows the price approaching an old high resistance level of 130p, a spot it hasn’t been to for nearly 7 years. Prior to that, it had fallen off from around the 375p mark a year or more earlier. These levels preceded the US manufacturing moves, the dispute with St Judes and the abrupt departure of the CEO of the time. It’s been tough for the company to win back investor support ever since then, that is until the heroic new strategy was put in place in 2018. Perhaps the support is coming back now with so much management success and strengthening of the board over the last two years culminating in the RUA acquisition. The name change to RUA Life Sciences should finally consign that long “AorTech” |
Posted at 13/6/2020 11:19 by nimbo10 Since Bones' note there seems to have been pretty good buying volume, most notable on 11th a trade for 18600 at 1.16 around 10:20 valued at 21k.MMs seem to be in accumulation mode. Some high net worth investors may well be coming on board. |
Posted at 08/6/2020 10:12 by bones I have just written a short research document of 4 pages plus some reference links, on the current state of play at Aortech/RUA following the “merger” between Aortech and RUA Medical Devices Ltd in April and the immense steps forward taken by those combined companies in the development to date in readiness for various trials of the heart valve and cardiovascular grafts. The piece briefly talks about:- The merger’s benefits in terms of vertical integration and combination of manufacturing expertise and valuable IP. - The current industry landscape and how Aortech/RUA could disrupt it. - The heart valve industry, current technologies and why Aortech/RUA have such a large opportunity to hurt the majors if they are successful. - The historical tendency for the majors to defend their positions by buying out disrupters. - The possibility that Aortech/RUA has two current projects that each could ultimately be worth many multiples of the current share price of Aortech/RUA. - The pipeline of other areas of devices that RUA has brought with it that could in future be exploited via the Elast-Eon IP platform. It does NOT discuss finances and future funding needs, which are inevitable at some stage. It does however cross-refer to documents where those subjects do get an airing, eg the Equity Development research notes. I would emphasise that this is, first and foremost, intended as an initial source of information, a “research starter pack” with cross referencing to various other sources of information. It is to be used as such and is not in any way a recommendation to invest. That decision is for someone after they have done their own research way beyond my little effort! It was written primarily for some high net worth individuals who expressed an interest through an associate of mine. If anyone here is interested in seeing the piece or knows any serious investors who might want to know a bit more information about the company for their own researches, please send a PM with name and email address and I’ll send a PDF of it to you. As I state on the document, this is not intended for wide distribution, is not for commercial purposes nor any recommendation to invest. Lest we all forget that this is still a high risk investment with plenty of challenges ahead for the management! |
Posted at 04/6/2020 08:28 by someuwin ...The clues are all there in that last post.They have a plan. The plan is working. The plan should deliver huge upside to patient investors! |
Posted at 27/5/2020 16:23 by bones It’s hidden as any speculative investors are too busy chasing Covid related stocks. They can’t see the wood for the trees. I’m sure it will change as Aortech’s story takes hold. |
Posted at 27/5/2020 09:55 by bones We look forward to the wider population of investors receiving an eyeful of Aortech’s assets. |
Posted at 22/5/2020 06:38 by cocker We have said it a million times here alone, the ridiculous spread puts investors off. Yes sometimes you can get within the spread and quite often you can not. Quite right in what you say though, 90.5p was selling price late yesterday afternoon, so a tick up on any buys should happen today. |
Posted at 18/5/2020 10:45 by bigwig Mind if I join in, I agree about the spread not being as wide as shown as I also bought this morning, fresh from success with BATM, this one looks interesting with a small market cap and that also puts off some investors but for me it makes it more attractive. I found the comments in this thread very helpful too. Will look to buy more in stages if they start moving up. |
Posted at 29/4/2020 14:39 by bones Nextlink. Not sure I want to see any kind of placing at these lowly prices. Company should be worth much more and then you might accept one to be fair to the investors. In any case, the company said the following just last month:”The Board is taking prudent steps to mitigate and manage its cashflow and the agreement with David Richmond to defer part of the cash consideration is part of that exercise. The Board is confident that the Enlarged Group is well equipped and operating in an essential industry to enable both AorTech and RUA to withstand this near-term uncertainty.” |
Posted at 20/4/2020 15:52 by bones On lockdown, basking in the sun and fast coming to the conclusion that a knockout £5 per share bid from an industry player would be absolutely splendid.The AIM market and its mostly short-sighted investors just don’t get it! The teams running Aortech/RUA deserve better and perhaps would be best served being owned by the industry that knows what it is aiming to achieve. Rant over. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
